These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 32321471)

  • 1. Cytology cell blocks from malignant pleural effusion are good candidates for PD-L1 detection in advanced NSCLC compared with matched histology samples.
    Zou Y; Xu L; Tang Q; You Q; Wang X; Ding W; Zhao J; Ren G
    BMC Cancer; 2020 Apr; 20(1):344. PubMed ID: 32321471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consistency Analysis of Programmed Death Ligand 1 Expression in Non-Small Cell Lung Cancer Between Pleural Effusion and Matched Primary Lung Cancer Tissues by Immunohistochemical Double Staining.
    Sun Z; Xiao X; Liang S; Ma H; Sun Y; Zhao L; Wang C; Chang X; Zhao H; Guo H; Zhang Z
    Lab Invest; 2024 Jun; 104(6):102058. PubMed ID: 38626874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
    Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
    Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of Ventana SP263 PD-L1 assay in endobronchial ultrasound guided-fine-needle aspiration derived non-small-cell lung carcinoma samples.
    Chauhan A; Siegel L; Freese R; Racila E; Stewart J; Amin K
    Diagn Cytopathol; 2021 Mar; 49(3):355-362. PubMed ID: 33142053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programmed death-ligand 1 immunoexpression in matched biopsy and liquid-based cytology samples of advanced stage non-small cell lung carcinomas.
    Jain D; Sukumar S; Mohan A; Iyer VK
    Cytopathology; 2018 Dec; 29(6):550-557. PubMed ID: 29938855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant pleural effusion cell blocks are reliable resources for PD-L1 analysis in advanced lung adenocarcinomas: a concordance study with matched histologic samples.
    Mahajan S; Nambirajan A; Gupta I; Gupta N; Gupta P; Jain D
    J Am Soc Cytopathol; 2022; 11(5):253-263. PubMed ID: 35589508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
    Heymann JJ; Bulman WA; Swinarski D; Pagan CA; Crapanzano JP; Haghighi M; Fazlollahi L; Stoopler MB; Sonett JR; Sacher AG; Shu CA; Rizvi NA; Saqi A
    Cancer Cytopathol; 2017 Dec; 125(12):896-907. PubMed ID: 29024471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
    Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P
    Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of ≥ 50% PD-L1 expression with the SP263 monoclonal antibody in non-small cell lung cancer patients.
    Li W; Song P; Guo L; Liu X; Guo C; Ying J; Gao S
    Thorac Cancer; 2019 Feb; 10(2):175-182. PubMed ID: 30536734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens.
    Lozano MD; Abengozar-Muela M; Echeveste JI; Subtil JC; Bertó J; Gúrpide A; Calvo A; de Andrea CE
    Cancer Cytopathol; 2019 Jul; 127(7):470-480. PubMed ID: 31245924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.
    Cruz-Rico G; Avilés-Salas A; Popa-Navarro X; Lara-Mejía L; Catalán R; Sánchez-Reyes R; López-Sánchez D; Cabrera-Miranda L; Aquiles Maldonado-Martínez H; Samtani-Bassarmal S; Arrieta O
    Pathol Oncol Res; 2021; 27():597499. PubMed ID: 34257548
    [No Abstract]   [Full Text] [Related]  

  • 12. Real-World Prevalence of PD-L1 Expression Among Tumor Samples From Patients With Non-Small-Cell Lung Cancer.
    Gelatti ACZ; Cordeiro de Lima VC; Freitas H; Werutsky G; Gaiger AM; Klock C; Viola PP; Shiang C; de Macedo MP; Lopes LF; De Marchi P; Albino da Silva EC; Moura F; Borges G; Zaffaroni F; Nunes Filho PR; Araujo LH; Mascarenhas E; Mathias C; Barrios C; Zukin M
    Clin Lung Cancer; 2020 Nov; 21(6):e511-e515. PubMed ID: 32389509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formalin fixation for optimal concordance of programmed death-ligand 1 immunostaining between cytologic and histologic specimens from patients with non-small cell lung cancer.
    Koomen BM; van der Starre-Gaal J; Vonk JM; von der Thüsen JH; van der Meij JJC; Monkhorst K; Willems SM; Timens W; 't Hart NA
    Cancer Cytopathol; 2021 Apr; 129(4):304-317. PubMed ID: 33108706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of Programmed Death-Ligand 1 (PD-L1) Immunohistochemical Expression on Cytology Specimens in Non-Small Cell Lung Carcinoma.
    Hernandez A; Brandler TC; Zhou F; Moreira AL; Schatz-Siemers N; Simsir A
    Am J Clin Pathol; 2019 Mar; 151(4):403-415. PubMed ID: 30534975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of PD-L1 immunocytochemistry using body-fluid cell blocks in patients with non-small-cell lung cancer.
    Song SG; Lee J; Koh J; Kim S; Chung DH; Jeon YK
    Diagn Cytopathol; 2020 Apr; 48(4):291-299. PubMed ID: 31930724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The detection of PD-L1 expression on liquid-based cytology in pleural effusion of lung adenocarcinoma and its prognostic evaluation: Between paired liquid-based cytology and cell block samples.
    Ma H; Jia J; Sun Z; Xiao X; Liang S; Zhao L; Zhang Z
    Diagn Cytopathol; 2024 May; 52(5):235-242. PubMed ID: 38263766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of immune checkpoint inhibitors according to PD-L1 tumor proportion scores in non-small cell lung cancer.
    Park S; Choi YD; Kim J; Kho BG; Park CK; Oh IJ; Kim YC
    Thorac Cancer; 2020 Feb; 11(2):408-414. PubMed ID: 31841269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 detection in histology specimens and matched pleural fluid cell blocks of patients with NSCLC.
    Grosu HB; Arriola A; Stewart J; Ma J; Bassett R; Hernandez M; Ost D; Roy-Chowdhuri S
    Respirology; 2019 Dec; 24(12):1198-1203. PubMed ID: 31209954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Correlation between the Expression of PD-L1 in Pleural Effusion of Lung Adenocarcinoma and the Clinicopathological Features and Molecular Changes].
    Ma H; Jia J; Guo H; Zhao H; Wang C; Zhao L; Sun Y; Li W; Zhang Z
    Zhongguo Fei Ai Za Zhi; 2020 Mar; 23(3):150-155. PubMed ID: 32209183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
    Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.